Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Assets (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Non-Current Assets for 6 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 46.27% to $9.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, up 46.27% year-over-year, with the annual reading at $9.2 million for FY2025, 46.27% up from the prior year.
  • Non-Current Assets hit $9.2 million in Q4 2025 for Insight Molecular Diagnostics, up from $6.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $127.4 million in Q2 2021 to a low of $5.4 million in Q4 2023.
  • Historically, Non-Current Assets has averaged $65.4 million across 5 years, with a median of $66.0 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 183.02% in 2021 and later tumbled 92.71% in 2023.
  • Year by year, Non-Current Assets stood at $120.4 million in 2021, then crashed by 38.09% to $74.6 million in 2022, then crashed by 92.71% to $5.4 million in 2023, then rose by 16.34% to $6.3 million in 2024, then skyrocketed by 46.27% to $9.2 million in 2025.
  • Business Quant data shows Non-Current Assets for IMDX at $9.2 million in Q4 2025, $6.5 million in Q3 2025, and $6.7 million in Q2 2025.